3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Hairy Cell
3
Hematologic Neoplasms
3
Burkitt Lymphoma
3
Waldenstrom Macroglobulinemia
2
Sezary Syndrome
2
Neuroblastoma
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Hodgkin Disease
2
Congenital Abnormalities
2
Breast Neoplasms
2
Teratoma
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Paraproteinemias
1
Interventions
plerixafor
1
Granulocyte Colony-Stimulating Factor
1
Blood Specimen Collection
1
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Paraproteinemias
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT01186224
2025-03-17
PHANTASTIC
University of Liverpool
Phase NA
Completed
60 enrolled